Loading...

ADIL ADIAL PHARMACEUTICALS INC Expansion Plans 8-K Filing

DL P

DL

ADIAL PHARMACEUTICALS INC

(ADIL)

2025 8-K

Warrant Agreement

Financial Results Update

FDA Meeting Insights

Nasdaq Compliance Notice

Financial Update

Equity Offerings

Increase in authorized shares

Loan Defaults (Secured, Uns...

Equity Offerings

Equity Offerings

Voluntary Delisting

Financial Statements

Rights Offerings

Management Change

Financial Results

Business Development

Corporate Update

Share Sale Agreement

CEO Agreement Update

PK Study Completion

Equity Plan Update

Management Changes

Entry Into a Material Defin...

Departure of Directors

Warrant Inducement Agreement

Appointment of COO

Special Meeting of Stockhol...

Earnings Release

Annual Meeting and Amendmen...

Amendment to Form 8-K Filing

Securities Purchase Agreement

Recasting Financial Informa...

Acquisition Agreement

Investor Conferences

Earnings Reports

Completion of Acquisition o...

Reverse Stock Split

Presentation at Conference

Purchase Agreement with Alu...

Delisting Notice

Earnings Reports

Material Definitive Agreement

Special Meeting of Stockhol...

Financial Results Announcement

Agreement with The Keswick ...

Regulatory Strategy Update ...

Delisting Notice

Securities Purchase Agreement

Regulatory Meetings for AD04

Acquisition Agreement

External Links:

On September 16, 2025, Adial Pharmaceuticals reported receiving positive feedback from the FDA regarding its AD04 drug for Alcohol Use Disorder in a meeting held on July 29, 2025, marking a key milestone for its Phase 3 trials. The FDA supported the trial design and confirmed primary efficacy endpoints, indicating alignment with the company's clinical development strategy.

AI Assistant

ADIAL PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.